Multiple interferon and virus response element cell-based fluorescence system

Abstract

The present disclosure refers to a method for a specific, versatile and sensitive detection of IFN-/virus-induced genes, a method for quantifying IFN potency and activity in a pharmaceutical preparation or biological sample, a method for distinguishing between IFN- and viral induction, and/or for distinguishing between different viruses, and a method for the quantification of virus activity. Also, the invention provides the necessary molecular tools like expression active response constructs, suitable cell lines, an array to perform the method and a kit.

Claims

1. An expression active reporter construct, comprising a response element, a transcriptional control element, a reporter DNA sequence, and a termination sequence, wherein the response element is an interferon-stimulated response element (ISRE) or a virus response element (VRE) comprising any one of SEQ ID NOs: 4-24.

2. The reporter construct according to claim 1, wherein the response element is attached to a flanking region of 20-100 nucleotides.

3. The reporter construct according to claim 1, wherein the transcriptional control element comprises a minimal promoter which comprises at least a TATAA or TATAA-like signal, a GC-Box, CAAT signal, and/or an AP-1 site.

4. The reporter construct according to claim 3, wherein the minimal promoter comprises a minimal CMV promoter, a HSV TK promoter, a SV40 promoter, a synthetic minimal promoter, a viral or cellular promoter, or an inducible promoter.

5. The reporter construct according to claim 4, wherein the transcriptional control element comprises a minimal CMV IE promoter from position 36, 53, or 74 from the transcriptional start site.

6. The reporter construct according to claim 1, wherein the reporter DNA sequence encodes a reporter protein that is an enhanced green fluorescent protein (EGFP), an EGFP-MODC fusion protein, or luciferase.

7. The reporter construct according to claim 1, wherein the termination sequence comprises a SV40 polyadenylation signal, and/or wherein the termination sequence is the termination sequence of bovine growth hormone (BGH).

8. The reporter construct according to claim 1, wherein the expression active reporter construct comprises an intron or enhancer.

9. A stable cell line expressing a reporter protein from an expression active reporter construct according to claim 1.

10. The stable cell line according to claim 9, which is a Vero, 293T, K562, MDCK, HT1080, or HepGR, or a liver cell line.

11. An array comprising at least one expression active response reporter construct, wherein the expression active response reporter construct comprises a response element, a transcriptional control element, a reporter DNA sequence, and a termination sequence, wherein the response element is an interferon-stimulated response element (ISRE) or a virus response element (VRE) selected from SEQ ID NO: 4 to SEQ ID NO: 109.

12. The array according to claim 11, comprising at least two expression active reporter constructs, wherein at least two reporter constructs have different response elements, and wherein the sequences of the response elements are selected from SEQ ID NO: 4 to SEQ ID NO:109.

13. The array according to claim 11, comprising at least thirteen different expression active reporter constructs, wherein at least thirteen reporter constructs have different response elements, and wherein the sequences of the response elements are selected from SEQ ID NO: 4 to SEQ ID NO:109.

14. The array according to claim 11, wherein the response elements of the reporter constructs comprise at least one sequence selected from SEQ ID NO: 4, SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO:10, and SEQ ID NO: 11.

15. The array according to claim 11, wherein the response elements of the reporter constructs comprise at least one sequence selected from SEQ ID NO: 12, SEQ ID NO: 13,SEQ ID NO:14, and SEQ ID NO: 58.

16. The array according to claim 11, wherein the reporter constructs have response elements that comprise SEQ ID NO: 4 (VREL-1), SEQ ID NO: 11 (PARP10), SEQ ID NO:16 (OAS3V2), and SEQ ID NO: 9 (USB18-M).

17. The array according to claim 11, wherein the reporter constructs have reporter constructs with response elements that comprise SEQ ID NO: 16 (OAS3V2), SEQ ID NO: 10 (IFIT3-2), SEQ ID NO: 4 (VREL-1), SEQ ID NO: 53 (GIP3-6-16), SEQ ID NO: 5 (VREL-2), SEQ ID NO: 12 (IFIT3-1), SEQ ID NO: 78 (GPB1-V), SEQ ID NO: 14 (VRE Con), SEQ ID NO: 58 (AB-VRE), SEQ ID NO: 62 (IFNA-V), SEQ ID NO: 33 (MX-1), SEQ ID NO: 15 (OAS3-V), and SEQ ID NO: 11 (PARP 10).

18. The array according to claim 11, wherein the reporter constructs have response elements that comprise SEQ ID NO: 104 (AB-VRE-M2), SEQ ID NO: 5 (VREL-2), SEQ ID NO: 4 (VREL-1), SEQ ID NO: 100 (VRE-G1), SEQ ID NO: 9 (USB18-M), SEQ ID NO: 101 (SYN-ISRE-2R), SEQ ID NO: 19 (PARP10-S), SEQ ID NO: 11 (PARP10), SEQ ID NO: 16 (OAS3V2), SEQ ID NO: 15 (OAS3-V), SEQ ID NO:18 (MX1-2-2), SEQ ID NO: 33 (MX1), SEQ ID NO: 62 (IFNA-V), SEQ ID NO: 23 (IFIT3-2S), SEQ ID NO: 10 (IFIT3-2), SEQ ID NO: 12 (IFIT3-1), SEQ ID NO: 24 (IFIT1), SEQ ID NO: 78 (GPB1-V), SEQ ID NO: 53 (GIP3-6-16), SEQ ID NO: 105 (AB-VRE-M), SEQ ID NO: 58 (AB-VRE), SEQ ID NO: 31 (HERC5), SEQ ID NO: 102 (SYN-ISRE-2), SEQ ID NO: 103 (B-VRE-3X), and SEQ ID NO: 74 (PSMP9-V).

19. The array according to claim 11, wherein the expression active response reporter construct is transfected into a stable cell line.

20. A method for detection of recombinant interferon induction, comprising the steps of: providing an array with expression active reporter constructs according to claim 1, transfection of the expression active reporter constructs into cells, exposing cells to a recombinant interferon, and detection of reporter activity.

21. The method of claim 20, wherein the reporter construct is in a 96-well plate or a 384-well plate.

22. A kit comprising an array according to claim 11, a buffer, and a stable cell line.

23. The kit of claim 22, further comprising an instruction sheet.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 Schematic representation of the GFP-based multiple IFN/Virus Reporter live cell System. The liver cell line, Huh-7, was treated with recombinant IFN- (100 IU/ml) for 6 hrs. Total RNA extraction was performed and subjected to whole genome microarray hybridization and analysis. An IFN-stimulated gene (ISG) Cluster was analyzed using bioinformatics by extraction of the Promoter and searching for ISRE/VRE using Promoser (Halees et al., 2003) and TFSEARCH, respectively. Several variations of ISRE/VRE sequence elements with their context regions were utilized for construction of EGFP reporters. Cell-based 96-well arrays were assembled for use with various treatments of IFNs and viruses.

(2) FIG. 2 Graphical scheme showing the minimal promoter of CMV IE promoter used for the IFN-responsive construct. TSS: transcriptional start site (SEQ ID NO:110); mutant (SEQ ID NO:111); ISRE (nucleotides 1-63 of SEQ ID NO:52). Numbers are in relation to TSS.

(3) FIG. 3 Reporter activity of EGFP reporter constructs. EGFP reporter constructs were used for transient transfection of Huh-7 cells for overnight. IFN- (100 U/ml) were added for 16 hr. Fluorescence was quantified as described in Methods. Reporter activity as fluorescence was assessed from images captured by BD automated bioimager and quantitated by ProXcell (as described in Example 1). Readings are MeanSEM of fold increase over control from fluorescence intensities of quadruplicate wells. ***p<0.001 AND *<0.01 using Student's t-test.

(4) FIG. 4 Early response performance comparison between EGFP and EGFP-MODC (destabilized EGFP). Reporter Expression constructs containing either wild type EGFP or unstable EGFP-MODC fusion protein were transfected onto Huh-7 cells. Cells were cultured in the presence or absence of 100 U/ml of IFN- for the indicated period of time. Fluorescence levels were measured (as described in Example 1). High resolution images were obtained automatically by BD high-content imager. Quantitation was performed with Proxcell imaging algorithm. Data is fold difference in MeanSEM (quadruplicate) from a representative experiment of two.

(5) FIG. 5 Dose-response characteristics of ISRE-containing EGFP-MODC reporter. The ISRE-containing destabilized EGFP reporter construct was used for transient transfection of Huh-7 cells. Increasing doses of IFN were added to the cells for 16 hr. Fluorescence was quantified (as described in Example 1). Reporter activity as fluorescence was assessed from images captured by BD automated bioimager and quantitated by ProXcell as described in Methods. Readings are MeanSEM of fold increase over control from fluorescence intensities of quadruplicate wells. ***p<0.001 AND *<0.01 using Student's t-test.

(6) FIG. 6 Differential expression of IFN and New Castle disease virus in human liver cells. Huh-7 cells (2104) were seeded in 96-well microplates and transfected with 50 ng/well of the ISRE/VRE GFP reporter constructs for 16 hr. IFN (100 IU/ml) or NDV (10 HA per well) were added for 16 hr; fluorescence were quantitated from captured high resolution images using high-throughput BD bioimager and ProxCell algorithm (Hitti et al., 2010). Fold changes were evaluated by hierarchal clustering centered with Spearman's correlation. The designations of sequencesexcept synthetic variations-were derived from gene names in which the sequence elements were derived from.

(7) FIG. 7 An image of live cells showing the induction by IFN (left) and mathematical/statistical graph of the result (right). A reporter with mutant response elements is as control.

(8) FIG. 8 Monitoring of early (6 hr) and late response (16 hr) to IFN and virus challenge in the cell-based multiple reporter assay. Huh-7 cells (2104) were seeded in 96-well microplates and transfected with 50 ng/well of the ISRE/VRE GFP reporter constructs for 16 hr. IFN (100 IU/ml) for early point (4-8 hr) or late point (16-20) hr; fluorescence were quantitated from captured high resolution images using high-throughput BD bioimager and ProxCell algorithm (Hitti et al., 2010). Fold changes were evaluated by hierarchal clustering centered with Spearman's correlation. The designations of sequencesexcept synthetic variations-were derived from gene names in which the sequence elements were derived from.

(9) FIG. 9 Early and late expression of IFN and New Castle disease virus induced activity. Huh-7 cells (210.sup.4) were seeded in 96-well microplates and transfected with 50 ng/well of the indicated ISRE/VRE GFP reporter constructs for 16 hr. IFN (100 IU/ml) or NDV (10 HA per well) were added for 16 hr; fluorescence were quantitated from captured high resolution images using high-throughput BD bioimager and ProxCell algorithm.

(10) FIG. 10 QPCR evaluation of reporter activity. Huh-7 cells were challenged with the IFN and virus as previously described in FIG. 6 legend. Total RNA was subjected to RTQPCR using specific primer/TaqMan probe specific to the EGFP mRNA.

(11) FIG. 11 Virus response sub-array. Reporter constructs that were differentially responsive to NDV and IFN, were further examined for responses to several types of viruses.

EXAMPLES

Example 1

(12) The following general methods were used in all subsequent Examples.

(13) Cells, IFNs, and Viruses

(14) Huh-7 cells were maintained in DMEM medium supplemented with 10% heat-unactivated fetal bovine Serum (FBS), 100 U/ml penicillin, 100 pg/ml streptomycin. Recombinant human rIFNa2a (Roferon) is from Hoffman-LaRoche, Basel, Switzerland and had specific activity of 2108 IU/mg. Recombinant human IFNy is from R & D systems. All viruses were obtained from ATCC and propagated in appropriate host cells. Encephalomyocarditis virus (EMCV), vesicular stomatitis virus (VSV, Indiana strain), Herpes simplex virus (HSV-I), respiratory syncytial virus, and influenza virus human H1N1 A/Puerto Rico/8/34 strain were obtained from the ATCC (Manassas, Va.). Virus preparations were clarified by low speed centrifugation, filtered through 0.22-pm membranes for sterility, and titrated on VERO (African Green Monkey Kidney cell line, ATCC) or by hemagglutinin assay (in case of RSV and flu virus). Virus stocks were aliquoted and stored at 70 C. until use.

(15) Microarray Assessment of IFN-Stimulated Genes in the Human Transcriptome

(16) Two whole genome expression analysis platforms were used, the OpArray whole transcriptome microarrays (Operon, Inc., USA) and whole transcriptome OneArray (Phalanx, Taiwan). The human liver cell line was treated with rIFN-2a (100 IU/ml) for 6 hr incubation, which is optimal for the induction of many IFN-stimulated genes. Total RNA was extracted using Tri Reagent (Molecular Research Center, Cincinnati, Ohio). The microarrays were used for cohybridization, using Genisphere kit (Genisphere, Inc., Hatfield, Pa.); labeled cDNA generated from total RNA (20 pg) using Cy3 and Cy5 for control (medium only) and experiment (IFN treatment), respectively; details were previously described (Khabar et al., 2004). Scanning are performed with ScanArray Scanner (Perkin Elmer, Inc.) and the intensity of green and red fluorescent signals from each spotted cDNA sequence on the microarrays were calculated using adaptive circle algorithm and mean intensity of the pixels. Pre-processing, filtering of erroneous signals, normalization procedures, and calculation of intensity ratios were previously described in detail (Khabar et al., 2004)

(17) Bioinformatics Analysis:

(18) The IFN-stimulated gene list was utilized to extract their promoter sequencesin addition tofirst intron and exonusing Promoser program. Promoser extract promoter regions based on transcriptional sites and alignment algorithms (Halees et al., 2003). Subsequently, a primary list of ISGs Promoters sequences were used to search for ISRE and VRE (e.g., IRF sites) using DNA Transcription Factor Binding Site Prediction TFSEARCH program context regions of60 bases that harbor the ISRE/VRE sequences were extracted and the information were used for the forward primers' sequences.

(19) Construction of IFN/Virus Response EGFP Reporters:

(20) The method used to generate the reporter constructs utilizes the use of the destabilized EGFP plasmid previously described (al-Haj et al., 2009) and ISRE/VRE sequences containing primers. The expression active PCR products were generated directly from the EGFP vector using two primers. The forward primer contains 18 bases at the 3end which targets a minimal promoter region of the CMV promoter upstream of the EGFP coding region, and the putative IFN/ISRE sequence context region. The reverse primer contains a complementary sequence to the downstream region of the poly (A) site. The oligonucleotides were custom-synthesized by Metabion (Germany). The PCRs were carried out using the following reagents and conditions: 2.5 U HotStart Taq (Qiagen) and 0.2 U Pfx polymerase (Invitrogen, Carlsbad, Calif.) mix, 2 pl (100-200 ng) of the vector template, 1 PCR buffer, 0.2 mM dNTP's, 0.2 pM primers, with the following cycle conditions: 95 C. for 12 min, 31 cycles of: 94C, 1 min., 51 C., 1 min., 72 C., 4 min., and a final extension at 72 C. for 7 min. The PCR products were purified using Qiagen PCR purification columns to eliminate the primers, small PCR products, buffer, and enzymes. The PCR products were finally eluted in sterile water. The PCR products were run on a 1.2% agarose gel and visualized by ethidium bromide under UV light to verify size and quality. The purified PCR products were used in the transfection experiments.

(21) Transient Transfection of ISG-Promoter Linked EGFP Reporter Constructs.

(22) The promoter-reporter constructs were used in transient transfection at 50 ng per 210.sup.4 cell/well in 96-well microplates. Transfection efficiency using cells in separate wells were evaluated using red fluorescent protein vector (TurboRFP, Invivogen). Transfections were performed in serum-free medium using LipofectAMINE 2000 (Invitrogen) for 6 h followed by replacing the medium with serum-supplemented medium. After 18 h incubation, IFNs or viruses were added for additional 18 h. Emission of green fluorescent levels are visualized by fluorescent microscopy.

(23) Imaging and Fluorescence Measurement:

(24) Efficiency and level of transfection were aided by monitoring the fluorescence from EGFP constnicts (optimum excitation wavelength: 488 nm and emission wavelength: 503 nm). Automated laser-fonis image capturing were performed using the high-throughput BD Pathway 435 imager (BD Biosciences, San Jose, Calif.). In all cases, exposure times and other Settings are kept constant to allow equal comparison of experiments. Automated identification and quantification are performed using Proxcell algorithms (Hitti et al., 2010). Data as fold increase over control are from mean values r standard error (SEM) of fluorescence intensiv. All transfections were performed in several replicates as indicated in the text. The variance in GFP fluorescence among replicate microwells was <6%; thus, with this minimum variance, experiments do not warrant transfection normalization. Image processing, segmentation, and fluorescence quantification was previously described (al-Haj et al., 2009). Student t-test was used when comparing two data groups while analysis of variance (ANOVA) was performed for each data Set having three or more data groups.

(25) Quantitative Real-Time PCR

(26) Isolated total RNA was reverse transcribed into cDNA using Superscript II (Invitrogen). The expression levels of EGFP mRNA and control housekeeping mRNA were assessed using TaqMan expression assay. First, reverse transcription was performed using Superscript II and Oligo dT primer (Invitrogen). A custom made Taqman primer and probe Set (Applied Biosystems) specific to EGFP reporter construct was used. The primers span the CMV promoter intron A in the EGFP vector to control DNA contamination. The 6-carboxyfluorescein (6FAM)-labeled TaqMan probe that target CMV exon 1-EGFP (exon 2) junction sequence was used. The probe design allowed further control of DNA contamination. The control GAPDH probe was labeled with a 5 reporter VIC dye (Applied Biosystems). The specificity for the cDNA of Taqman primer was tested on a negative control containing plasmid DNA. The endogenous control was used for normalization. Real time PCR was performed in multiplex in the Chroma 4 DNA Engine cycler (BioRad). The final results are expressed as normalized fold change in controls.

Example 2

(27) VRE and ISRE-containing promoters that are responsive to IFN were searched by first profiling gene expression in the Huh7 liver cell line. 59 strongly induced (6 fold) gene cluster (FIG. 1, Table 1) have been selected.

(28) TABLE-US-00002 TABLE 1 Table 1: Total RNA samples from mock-treated or IFN- (100 U/ml)-treated cells were extracted and subjected to microarray-based hybridization. Microarray experiments were performed at least twice with two different whole transcriptome oligonucleotide microarray systems (as described in Example 1). Induction, Gene Description Ratio, Mean SEM N ARF1 ADP-ribosylation factor 1 5.20 0.20 2 C10orf118 Uncharacterized protein C10orf118 10.00 4.00 2 C3 complement component 3 5.58 1.93 2 CASP7 caspase 7, apoptosis-related cysteine peptidase 6.11 0.80 2 CXCL10 chemokine (C-X-C motif) ligand 10 7.82 0.48 3 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 13.00 4.28 2 EPSTI1 epithelial stromal interaction 1 (breast) 19.00 2.00 2 G1P2 ISG15 ubiquitin-like modifier 16.72 12.31 2 G1P3 interferon, alpha-inducible protein 6 16.00 2.00 3 GBP1 guanylate binding protein 1, interferon-inducible, 67 kDa 12.65 3.62 4 GBP3 guanylate binding protein 3 5.92 0.86 3 HERC5 hect domain and RLD 5 18.02 2.56 2 IFI27 interferon, alpha-inducible protein 27 29.70 15.47 4 IFI44 interferon-induced protein 44 17.31 8.63 2 IFIH1 interferon induced with helicase C domain 1 8.24 0.07 2 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 21.20 4.10 8 IFIT2 interferon-induced protein with tetratricopeptide repeats 2 18.72 6.44 3 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 18.92 14.53 4 IFIT5 interferon-induced protein with tetratricopeptide repeats 5 5.61 . 1 IFITM1 interferon induced transmembrane protein 1 (9-27) 16.58 6.62 2 IRF1 interferon regulatory factor 1 9.25 . 1 ISG15 ISG15 ubiquitin-like modifier 9.02 6.77 2 ISG20 interferon stimulated exonuclease gene 20 kDa 4.20 0.87 2 ISGF3G interferon regulatory factor 9 6.05 . 1 LAP3 leucine aminopeptidase 3 6.33 1.12 2 MATR3 small nucleolar RNA host gene 4 (non-protein coding) 21.38 7.91 2 MT2A metallothionein 2A 6.67 1.73 2 MX1 myxovirus (influenza virus) resistance 1 17.66 2.73 4 MYD88 myeloid differentiation primary response gene (88) 5.01 . 1 NPIP nuclear pore complex interacting protein 10.88 7.98 2 NT5C3 5-nucleotidase, cytosolic III 6.66 0.78 4 OAS1 2,5-oligoadenylate synthetase 1, 40/46 kDa 19.40 4.68 6 OAS2 2-5-oligoadenylate synthetase 2, 69/71 kDa 14.00 2.00 2 OAS3 2-5-oligoadenylate synthetase 3, 100 kDa 6.17 . 1 OASL 2-5-oligoadenylate synthetase-like 7.72 0.00 2 P4HB prolyl 4-hydroxylase, beta polypeptide 4.89 0.46 2 PARP10 poly (ADP-ribose) polymerase family, member 10 8.31 1.69 4 PLSCR1 phospholipid scramblase 1 9.41 0.58 2 PPIA peptidylprolyl isomerase A (cyclophilin A) 20.34 1.35 2 PRIC285 Peroxisomal proliferator-activated receptor A-interacting 5.82 0.11 2 complex 285 kDa PSMB8 proteasome (prosome, macropain) subunit, beta type, 8 10.17 1.40 2 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 11.95 0.81 3 PSMD1 proteasome (prosome, macropain) 26S subunit, non- 8.45 1 ATPase PSME1 proteasome (prosome, macropain) activator subunit 1 3.64 1 SAMD9 sterile alpha motif domain containing 9 7.18 2.97 2 SELPLG selectin P ligand 64.43 1 SLC15A3 solute carrier family 15, member 3 6.00 0.04 2 SP100 SP100 nuclear antigen 8.00 2.00 2 STAT1 signal transducer and activator of transcription 1, 91 kDa 11.37 4.19 4 STAT2 signal transducer and activator of transcription 2, 113 kDa 9.35 5.76 2 TAP1 transporter 1, ATP-binding cassette, sub-family B 13.98 2.90 4 (MDR/TAP) TMEM67 transmembrane protein 67 22.00 1 TRIM22 tripartite motif-containing 22 19.00 2.00 2 UBE2L6 ubiquitin-conjugating enzyme E2L 6 9.98 5.86 3 USP18 ubiquitin specific peptidase 18 14.33 3.50 5 TMEM67 transmembrane protein 67 22.00 1 TRIM22 tripartite motif-containing 22 19.00 2.00 2 UBE2L6 ubiquitin-conjugating enzyme E2L 6 9.98 5.86 3 USP18 ubiquitin specific peptidase 18 14.33 3.50 5 Data are Mean SEM of normalized ratios. N: number of replicate spots.

(29) Their promoters have been bioinformatically extracted and regions that contain VRE and ISREs (FIG. 1) have been searched.

(30) From each promoter, sequences matching the consensus elements of IRF-1, IRF-2, STATx, and ISRE (80% match) were extracted with their flanking region of 40-70 nucleotides; then, 100 VRE/ISRE regions were compiled (Table 2).

(31) TABLE-US-00003 TABLE2 SequenceInformationforISRE/VREregions SEQIDNO: Genecluster Sequence SEQIDNO:4 VREL1 GGGAAACCGAAACTGGGGAAACCGAAACTGGGGAAACCGAAAC TGGGAAACCGAAAC SEQIDNO:5 VREL2 GGAAACCGAAAGGGGAAAGTGAAACTAAAGCTGAAACCGAAAG GGGAAAGTGAAACTAAAGC SEQIDNO:6 GP3-6-16 GGGAAAATGAAACTCGGAGCTGGGAGAGAGGGGAAAATGAAAC TGCAGAAATAGAA SEQIDNO:7 MX1-1 GCTAGGTTTCGTTTCTGCGCCCCACAGGGTCTGTGAGTTTCATTTC TTC SEQIDNO:8 MX1-2 TGAGTTTCGTTTCTGAGCTCCTTTCATTTTCACCGGTTTCAATTCTC CTCTGGA SEQIDNO:9 USB18-M CTCCCGGCGCGGAGGCCGCTGTAAGTTTCGCTTTCCATTCAGTGG AAAACGAAA SEQIDNO:10 IFIT3-2 GATTCTGTTTCAGTTTCCCCTCAAGAGGGATCTTGATAGGGTTCCA TCAGTTTCACTTTCCTTTCCCCTTTCATCC SEQIDNO:11 PARP10 CCTCCTTCCGTCTTTCAGTT TCACTTTTGTTTTCCTGCTCCTGCTCCCTC SEQIDNO:12 IFIT3-1 GTTTCATTTTCCTCCTCCCAACGATTTTAAATTAGTTTCACTTTCCA GTTTCCTCTTCCTT SEQIDNO:13 GBP1-V AAAAAACTGAAACTCAGCCTGAAAGATGAACAGAACAAAACAG AAATCCT SEQIDNO:14 VRECon GAAAGTGAAAAGAGAAATGGAAAGTGGAAAAGGAGAAACT SEQIDNO:15 OAS3-V AGTGTCTGATTTGCAAAAGGAAAGTGCAAAGACAGCTCCT CCCTTCTGAGG SEQIDNO:16 OAS3-V2 TTCGGAGAGCCGGGCGGGAAAACGAAACCAGAAATCCGAAGGC CGCGCCAG SEQIDNO:17 MX1-1-2 GCTAGGTTTCGTTTCTGCGCCCCACAGGGTCTGTGAGTTTCATTTC TTCGCG SEQIDNO:18 MX1-2-2 TGAGTTTCGTTTCTGAGCTCCTTTCATTTTCACCGGTTTCAATTCTC CTCTGGAG SEQIDNO:19 PARP10S CTCCTTCCGTCTTTCAGTTTCACTTTTGTTTTCCTGCTCAGTTTCAC TTTTGTTTT SEQIDNO:20 DZIP1 CAGCTTCAGTTTTCCTAATGACAGTGAGTCATTTCTTCTCTCTCTTT T SEQIDNO:21 DZIP1-2 CCATTTCCCTCCCTCCTCTCATAGACAACCGATATATATCTTTCACT TTGGTG SEQIDNO:22 IFIT3-1-1 GTTTCATTTTCCTCCTCCCAACGATTTTAAATTAGTTTCACTTTCCA GTTTCCTCTTCCTT SEQIDNO:23 IFIT3-2S GATTCTGTTTCAGTTTCCCCTCAGTTTCACTTTCCTTTCCCCTTTC AGCAGTTTCACTTTCCTTTCCCCTTT SEQIDNO:24 IFIT1 TCCGCTAGCTTTAGTTTCACTTTCCCCTTTCGGTTTCCCTAGGTTTC CAACTTG SEQIDNO:25 IFIT2 AGTCCTGCCAATTTCACTTTCTAGTTTCACTTTCCCTTTTGTAACGT CAGCTG SEQIDNO:26 TMEM67 CCTTCTCTTTCCCTTTCCAGCACTTTGATTCCTTGTGGTGTCTGTTT CTGTTTTGTTAGTAATTTCATG SEQIDNO:27 MATR3-1 ATCTCCATCAAACCAAGATCCTAAGGGCTGGAAGTTTGTCTTTTCC ATCATTG SEQIDNO:28 MATR3-2 AAAGTTTGACTTTCTCTGCACAGTTCCACTTTCAGAGTTTTGCTTT TGTTG SEQIDNO:29 MATR3-3 TCTCATTTTCATTTTTACCTGTTTTGTCTTACTTTGTACTTTACCCAG TTTCGCTTTATCATCTG SEQIDNO:30 OAS1 GATGATCTTTCCACTTCCTGGTTTTTCTGA CTTTTTTTCTTTTTGCAGTG SEQIDNO:31 HERC5 GTTTCCTTTTCCTTTTCGATTCCGCCCCCTAACATTATGTTTCGTTT TCCACTG SEQIDNO:32 USP18 CCAGCTCCCGGCGCGGAGGCCGCTGTAAGTTTCGCTTTCCATTCA GTGGAG SEQIDNO:33 MX1 GCTAGGTTTCGTTTCTGCGCCCCACAGGGTCTGTGAGTTTCATTTC TTCGCG SEQIDNO:34 MX1-2-3 TGAGTTTCGTTTCTGAGCTCCTTTCATTTTCACCGGTTTCAATTCTC CTCTGGAG SEQIDNO:35 IFI44 GGGCTGGGCACACTGAGTTTCAGTTTCCTTTCTCTGAGTCTTTGA AGCTTCG SEQIDNO:36 IF144-2 GGTAAATGTCTTTCTGCTTTTCATTTTTCCTAGCTAGCAT TAGTCTCTCTG SEQIDNO:37 DDX58 CCGCTAGTTGCACTTTCGATTTTCCCTTTAGTTATTAAAG TTCCTATGCAG SEQIDNO:38 ISG15 AGTCCCCGCCACTTTTGCTTTTCCCTGTCTTTCGGTCATTCGGTTT TGTTTCTTCCG SEQIDNO:39 STAT1 GCTGCCTTTTCTCCTGCCGGGTAGTTTCGCTTTCCTGCGCAGAGTC TGCGGAG SEQIDNO:40 IPARP10-1 CCTCCTTCCGTCTTTCAGTTTCACTTTTGTTTTCCTGCTCCTGCTCC CTCG SEQIDNO:41 IFIH1 AATTCGCTTTCCTTTTCTGTTTCCCGCGGTGTCCTTAACCAAAGGC CTCCTCTCTTCA SEQIDNO:42 CASP7-1 TGATATCTTATTGIGGTTFTGCTTTGCATTTCCCTGTGAGCACCTTT TCATATG SEQIDNO:43 CASP7-2 CACTTCTTTCAAAGTGGTTTCTTTCAGTTTTCCTATTAAGTTCCTGT GTTGCTTCTTG SEQIDNO:44 CASP7-3 AGTTTTCTGTCATAATTTCTTTTCTACCCTTTTCTCTTTGCTCCTTCT GAGACA SEQIDNO:45 CASP7-4 CCATTCTTTTATTCCTTTACCTTTGCTTTCACTTTACTCTACCCTTAA TTCTTTCTTG SEQIDNO:46 NT5C3-1 ACTCTTTGCTATTTAGTTTCATTTTTGTTTTAAGTTTCACTTTGCAG CTGTTTCTTTTT SEQIDNO:47 NT5C3-2 AGGTTCCTCTTTTCTTTCCAGAGCCAGTTGACAGATTTACCTTCTC TTTAAG SEQIDNO:48 NT5C3-3 ACAGTTTTAGCTTTACAATTTTTTTTCTCTTTCCTTTTGTTGTGAAT TCATTTACCTAACG SEQIDNO:49 SAMD9 ATTTGACTTCCTCTTTTCCTAACTGAATACTCTTTATTTCTTTATCCT GCCTAAGAACTT SEQIDNO:50 C13ORF18 CAATTTCACTTTTATTCCTCTTTCTTCTCCTTACCTATTTTTGACACA TTTATTCAGTATG SEQIDNO:51 PSMP8 CTGTGGCTTTCGCTTTCACTTCCTCCTCTTTCGCTTTCACTTCCTCC CCGAGAG SEQIDNO:52 ISRE-74 AGCTTTAGTTTCACTTTCCCCTTTCGGTTTCAGCTTTAGTTTCACTT TCCCCTTTCGGTTTCCG SEQIDNO:53 GIP3-6-16 GGGAAAATGAAACTCGGAGCTGGGAGAGAGGGGAAAATGAAAC TGCAGAAATAGAAACTG SEQIDNO:54 IFNA4 AAGTAAAGAAAGTGAAAGTGAAAAGGAGATTGGAAAGCAAGGA AAGGAGAAACG SEQIDNO:55 7XVRE1 GAAAGTGAAAGTGAAAGTGAAAGTGAAAGTGAAAGTGAAAGTG SEQIDNO:56 PRD2X GAAAGTGAAAAGAGAATTGGAAAGCGAAAGTGAAAAGAGAATT GGAAAGCG SEQIDNO:57 7VRE2 AAGTGAAAGTGAAAGTGAAAGTGAAAGTGAAAGTGAAAGTGAA AGTG SEQIDNO:58 AB-VRE AGAAATGGAAAGTAGAAATGGAAAGTGAGAAGTGAAAGTGAGA AGTGAAAGTG SEQIDNO:59 VREL-3 GGGAAAGAGAAACCGGAAAAGCGAAACTGGAAAGAGAAACCGG AAAAGCGAAACTG SEQIDNO:60 ISG15-M ACTTTTGCTTTTCCCTGTCTTTCGGTCATTCGGTTTTGTTTCTTCCG GGAAAGGGAAACCGAAACTGAAG SEQIDNO:61 IFIT2-M AAGAAAAAGAGTCCTGCCAATTTCACTTTCTAGTTTCACTTTCCCT TTTGTTGAAGGGAAACAAACAAAAAGGAA SEQIDNO:62 IFNA-V GAGAAACATAAAGAGTGCATGAAGGAAAGCAAAAACAGAAATG GAAAGTGGCCCATTAAGAAAGTGGAAATCAG SEQIDNO:63 IFNO-V CACAAATGAAAACAGTAAAAGAAACTGAA AGTACAGAGAAATGTTCAGAAAATGAAAACCATGTGT SEQIDNO:64 IFNA5 TAGAAAGAGCATAAAAGAAAGCAAAAAGAGAAGTAGAAAGTAG GCAAGAAAATGGAAACTGTGACCTTG SEQIDNO:65 RGS20-V CAGCAAAGTGGAACTTAAGAGGGGAAGTGAAACAGGGAAATGC AAGGAGAAAGGCGAAAG SEQIDNO:66 C13ORF18-V CTGAAAGATGACTCAGTTAAGAAGCTGGAAAATAAAACCAGGTC TTATTCTGAACTGAAAGTC SEQIDNO:67 SELPLG-M AGATGGGCACTGTTTCTTATCCCAATTTTACAGATGGGAAAACTGA AGCTCAGGGAGGCAAG SEQIDNO:68 PKR-V AGTAGAAAAGAGCAAGTCTAAGGAATATCTAGAAAAGAGGAAGT TAGAACCATAGAAAAGG SEQIDNO:69 PKR-I TGAATTATTTCTCCTCCTTCAATTTCAGTTTGCTCATACTTTGTGAC TTGCGGTCACAGTG SEQIDNO:70 IF127-1 ATGAGGGGAGAAAGATGTCTGCAGTTTCGGTTTCCTGGAAAATGA AACCTGG SEQIDNO:71 IF27-2V AGTGTCTGATTTGCAAAAGGAAAGTGCAAAGACAGCTCCTCCCTT CTGAGG SEQIDNO:72 TMEM67-V TGTAAATGGAAAAACGAAATGACAAATAATTATGAAAGAGGCATC CATTTG SEQIDNO:73 TAPI TGAGCAGGCGGCCGCTTTCGATTTCGCTTTCCCCTAAATGGCTGA GCTTG SEQIDNO:74 PSMP9-V CAGCCATTTAGGGGAAAGCGAAATCGAAAGCGGCCGCCTGG SEQIDNO:75 IFITM1-V ACAGCAGGAAATAGAAACTTAAGAGAAATACACACTTCTGAGAA ACTGAAACGACG SEQIDNO:76 ISG15-V TGCCTCGGGAAAGGGAAACCGAAACTGAAGCCAAATTTGGCCAG SEQIDNO:77 IFIT2-V TGTAACGTCAGCTGAAGGGAAACAAACAAAAAGGAACCAGAGG CCACG SEQIDNO:78 GPB1-V AAAAAACTGAAACTCAGCCTGAAAGATGAACAGAACAAAACAG AAATCCTG SEQIDNO:79 GPB3-AV ACACGGTTATAGACAAAGAAAAAACTGAAACCCAGCATCAAAGA GGAACAG SEQIDNO:80 GPB3-BV TACAAAATGGAAAAACAGAACAAAACAGAAAACCTAAAGCTGTA TTGCTGG SEQIDNO:81 C10ORF18 AGTAGTAAGTTTTGCTTTACAAATTCTTACATTGCAGAATCGTCTG CATCAGCTAG SEQIDNO:82 PLSCR1V CGCCAGCGCGGGAACCGGGAAAAGGAAACCGTGTTGTGTACGTA AGATTCG SEQIDNO:83 OAS3V-2 GCTGCTAGAAAGAAACGAAACTGAAAGCAGGGAATG SEQIDNO:84 EPSTI1 CTTTGTAGGTTTTTGTTTTCTTTTGATTTCAGTTTCCATTTCCTCTG SEQIDNO:85 SP100 GTTAAATACTTTCACTTCTCTTTTCCCCATTTGGGCGGAGCCCTTT CTGAGTCAGTCG SEQIDNO:86 NFKBI TGCAGGGAAGTACCGGGAAGGACTTTCCAGCGCAGGGAGTTTCT CCGCTTGGAAATTCCCCGG SEQIDNO:87 IRF-7-V GTAACAAAAGCGAAACTCCATCTCAAAAAAAGAAACGCAAGG SEQIDNO:88 IFNB AAATGTAAATGACATAGGAAAACTGAAAGGGAGAAGTGAAAGTG GGAAATTCCTCTGAATG SEQIDNO:89 IFNB-2 CTAAAATGTAAATGACATAGGAAAACTGAAAGGGAGAAGTGAAA GTGGGAAATTCCTCT SEQIDNO:90 USB18-V TGCTATTATGAAGGAAAAAAGTGAAATGGAAATTAAAAAC SEQIDNO:91 GAS CTCGGGAAAGGGAAACCGAAACTGAAGCC SEQIDNO:92 GAS-2 AGCCTGATTTCCCCGAAATGACGGCAGCCTGATTTCCCCGAAATG ACG SEQIDNO:93 CXCL-10A TTTCAGAAACAGTTCATGTTTTGGAAAGTGAAACCTAATTCACTAT TACCAAAAAAAGAGGAGCAGAGG SEQIDNO:94 CXCL-10B TGATGTTTTCATTCAGGGACTTGAAACTTGTTTTAACACATGAGCA ATGTTTTCCCTCAAAATAG SEQIDNO:95 IRF-9 AAGGCCCTCCCTGGAGGAGAACTGAAACTTAGGGTGGGGACTGT AGAAAG SEQIDNO:96 myd88 AGGGCGGCGCAGGGCGGCGCTTCTCGGAAAGCGAAAGCCGGCG GGGCG SEQIDNO:97 IRF-3 CTTCTGAGTCTTAGAGAAAAAGGAACTGGAGCCCCAGACC SEQIDNO:98 IFNA17 AACACATGTAGAGAGTGCAAAAAGAAAGCAAAAACAGACATAGA AAGTAA SEQIDNO:99 IFNA1-V2 GAGTGCATGAAGGAAAGCAAAAACAGAAATGGAAAGTGGCCCA GAA SEQIDNO:100 VREGI GGGAAACCGAAAGTGGGAAACCGAAAGTGGGAAACCGAAAGTG GGAAACCGAAAGTG SEQIDNO:101 SynISRE-2R TACTTTCGCTTTCCACTTTCGCTTTCCTCACTTTCGCTTTCCTACTT TCGCTTT SEQIDNO:102 synISRE-2 GGGAAACCGAAACTAGGAAACCGAAACTGAGGAAACCGAAACT GGAAACCGAAACTA SEQIDNO:103 B-VRE-3X GAGAAGTGAAAGTGAGAAGTGAAAGTGAGAAGTGAAAGTG SEQIDNO::104 AB-VRE-M2 AGAAATGGAAAGTGAGAAGTGAAAGTAGAAATGGAAAGTGAGA AGTGAAAGTG SEQIDNO::105 AB-VRE-M AGAAATGGAAAGTAGAAATGGAAAGTACTGCGAGAAGTGAAAGT GAGAAGTGAAAGT SEQIDNO:106 OAS1-V AGTGTCTGATTTGCAAAAGGAAAGTGCAAAGACAGCTCCTCCCTT CTGAGG SEQIDNO:107 OAS3-V2-2 GCTGCTAGAAAGAAACGAAACTGAAAGCAGGGAATG SEQIDNO:108 SYNVRE-1 GGGAAACCGAAAGTAGGAAACCGAAAGTGAGGAAACCGAAAGT GGAAACCGAAAGTA SEQIDNO:109 VRE-G2 GGGAAAGCGAAAGTGGGAAAGCGAAAGTGGGAAAGCGAAAGTG GGAAAGCGAAAGTG

(32) The VRE and ISRE sequences are found in IFN genes and IFN-stimulated genes, and partially overlap each other, particularly the core sequence AANNGAAA with the following consensus sequences GAAANNGAAASY (SEQ ID NO:1), wherein S is G, or C, and Y is T, or C, and N is A, C, G, or T/U; or GAAAANNGAAASY (SEQ ID NO:2), wherein S is Q or C, and Y is T, or C. and N is A, C, Q or T/U, or RNGAAANNGAAACT (SEQ ID NO:3), wherein N is A, C, G, or T/U (also in complementary strand), respectively (Savitsky et al., 2010; Pierre et al., 2009).

Example 3

(33) In order to proceed with constructing the virus/IFN responsive constructs the VRE/ISRE response GFP reporter were optimized by assessing several IFN-responsive reporter constructs using a consensus ISRE with different minimal promoters (-36, -53, and -74 from the transcriptional start site following IE CMV promoter) (FIG. 2). The optimal -74 CMV reporter response required the following cis-acting elements: TATA box, GC-Box, CAAT signal, and AP-1 site. Further minimal promoter (53) contained only the TATA box but it is necessary to extend the length beyond the TATA box with additional 24 nucleotides since 36 region minimal promoter which contains only the TATA box failed to induce IFN response.

(34) In this example, Huh-7 cells were transfected with the reporter using 74 or -53 minimal promoter fused with standard IFN-responsive elements (as shown in FIG. 2). Additionally, mutant 53 promoter was used (sequence showing in FIG. 2). There was indeed significant responses with 74 and 53 constructs but not with 36 constructs. 74 constructs gave higher induction in contrasts to 53 constructs (FIG. 3).

(35) The use of the MODC C-terminus amino acids to destabilize the GFP protein contributed to better and earlier response (e.g., four to eight hours, FIG. 4) to IFN since MODC contains the protein instability determinants, PEST, known to occur in many proteins with short half life (Li et al., 1998). The benefit of earlier response is to allow flexibility in assay development and alternative drug screening approaches. Overall, the reporter construct had excellent linear dynamics response (1 IU/ml-100 IU/ml) sensitivity, and rapid kineticsFIG. 5).

Example 4

(36) Approximately 100 IFN/virus responsive GFP constructs (FIG. 1) were created. Sequence information was obtained from the bioinformatics (Table 2). The ISRE/VRE appears to be heterogeneous in terms of the sequence element reiterations and deviations from their Consensus, the number of ISRE repeats and their distribution in the entire promoter. Thus, the GFP reporter array was created so that differential fluorescence patterns from reporters with different sequence element heterogeneity due to IFN and virus can be monitored. The GFP 96-well microplate arrays contain lyophilized DNA for use in a number of transfection array experiments.

(37) The Huh-7 cells were transfected with the VRE/ISRE GFP constructs and then treated with medium, IFN or virus for 6 and 16 hr duration, representing early and late response; respectively. IFN was able to induce a significant subset of both ISRE and VRE containing constructs at 16 hr. In many instances, the VRE/ISRE act as common signature for both IFN and virus response but there are distinct patterns between IFN and the New Castle disease virus (NDV) responses (FIG. 6). Using hierarchal clustering normalized to Spearman's rank correlation, distinct patterns were observed that distinguishes IFN and NDV.

(38) There was a subset of GFP reporters that respond more strongly to virus than IFN and vice versa (FIG. 6, right and left column, respectively). FIG. 7 shows an image and graph example of the performance of the reporter. Within IFN responsive subset, there were distinct differential reporter responses ranging from very weak effect to stronger effects (1.5-33-fold). The strongest IFN-specific effect was observed with two synthetic sequences (designated, as VREL-1 (SEQ ID NO: 4) and VREL2 (SEQ ID NO: 5) that comprise four copies of GGGAAACCGAAACTG (nucleotides 1-15 and 31-45 of SEQ ID NO:4) or GAAACTAAAGCTG (nucleotides 21-33 of SEQ ID NO:5) repeats (30-33 fold increase). The naturally derived sequences GIP3-6-16 (SEQ ID NO: 53), MX1-1(SEQ ID NO: 33), MX1-2(SEQ ID NO: 8), USB 18-M (SEQ ID NO: 9), IFIT3-2 (SEQ ID NO: 10), and PARP10 (SEQ ID NO: 11) caused strong induction by IFN (.about.2.0 fold, p<0.0001) but with variable levels of induction by the virus (FIG. 8, Table 3).

(39) TABLE-US-00004 TABLE 3 Table 3: Huh-7 cells were transfected with different constructs and then treated with IFN for brief (4-8) or longer duration (24 hr). Subsequently, fluorescence was quantified and fold ratio on control (no IFN treatment) are shown. IFN, IFN, late NDV, ID early SEM response 24 hr GIP3-6-16 12.00 1.00 29.64 3.20 PARP10-S 12.56 25.91 8.00 MX1 10.82 0.93 24.63 7.38 MX1-2 11.84 0.51 22.11 9.51 VREL-1 15.58 1.25 21.00 2.30 USB18-M 10.58 0.78 20.90 9.35 VREL-2 5.82 0.54 17.80 2.60 IFIT-M1-V 4.00 0.08 16.59 4.96 OAS3V2 5.50 16.24 15.68 IFIT1 10.28 0.08 15.99 6.84 VRE-G1 1.60 14.71 5.10 IFIT3-2 9.80 0.90 14.00 9.40 SYNVRE-1 2.43 13.23 7.10 PARP10 10.87 0.60 13.00 3.20 IFI27-1 0.81 12.49 7.04 IFIT3-2 S 5.90 0.50 12.33 2.10 VRE-G2 1.00 12.24 4.00 ISG-15-M 10.70 0.26 12.21 3.00 ISRE 5.60 0.04 12.00 0.08 standard SYN-ISRE-1 3.20 11.28 7.00 OAS3V 7.43 11.25 6.50 STAT1 2.64 0.28 9.50 2.70 ISG15-V 1.08 9.49 6.84 SYNISRE-2 3.90 9.03 8.10 EPSTI1 6.01 8.14 5.47 USP18 5.72 0.41 7.93 2.81 SYN-ISRE- 1.60 7.86 2.50 2R PSMP9-V 6.42 7.85 8.57 SYNVRE-2 1.62 7.54 8.30 NT5C3-1 1.97 0.20 7.46 4.54 GAS 3.71 7.45 5.58 IFIT2 5.33 0.50 7.25 2.80 7XVRE1 10.91 0.65 7.03 3.11 TAP1 1.13 6.65 2.80 7VRE2 8.92 0.83 5.90 2.94 IFNA-V 0.93 0.30 5.81 0.98 PSMP8 8.29 1.27 5.63 2.08 PRD2X 4.03 0.72 5.51 4.14 CASP7-1 1.94 0.62 4.87 0.84 IFI44 3.80 0.52 4.70 1.97 HERC5 3.75 0.22 4.57 7.75 B VRE 3X 4.26 4.00 9.00 AB-VRE-M2 3.74 4.00 9.00 AB-VRE 3.07 0.58 3.75 5.10 DDX58 3.02 0.22 3.02 2.97 AB-VRE-M 3.28 3.00 7.00 VREL-3 3.26 0.13 2.99 2.51 GBP-GAS 2.20 0.14 2.94 0.72 IFIT-M 1.31 0.20 2.64 4.10 AB-VRE-M3 3.99 0.16 2.48 2.50 GPB3-AV 1.06 2.20 0.90 VRE-2B 0.60 2.12 1.90 IFNO-V 0.67 0.07 2.09 2.39 IFIT3-1 1.85 0.10 2.01 5.00 A VRE 3X 1.87 2.00 3.00 CXCL10A 2.02 1.96 2.07 OAS3V2 1.95 2.40 PLSCR1V 1.36 1.89 1.07 CASP7-2 1.21 0.20 1.82 1.03 ISRE-2B 1.60 1.80 1.10 TMEM67-V 1.80 1.68 0.94 IRF-G 0.80 1.55 1.40 GPB1-V 1.36 0.31 1.50 1.68 SAMD9 0.59 0.26 1.42 0.60 PKR-V 1.39 0.63 1.40 0.63 MYD88-74 1.49 1.36 1.60 MATR3-2 1.75 0.47 1.35 0.24 CASP7-4 2.12 0.38 1.35 0.49 GAS-2 1.18 1.30 1.18 IRF3 0.90 0.12 1.24 0.70 NT5C3-2 1.02 0.08 1.22 0.53 DZIP1(2) 1.06 0.10 1.21 0.78 IFNB-2 5.27 1.19 1.19 IFI27-2V 0.84 1.18 1.03 CXCL10B 1.23 1.17 1.25 TMEM67 0.74 0.20 1.15 0.92 IRF-7-V 1.80 1.12 0.89 4X-GAS-2 1.30 0.12 1.11 0.90 MATR3-3 1.13 0.15 1.07 0.85 IFIHI 1.11 0.30 1.06 0.43 IFNA5 0.87 0.08 1.05 0.79 OASI 1.87 0.80 1.01 1.31 IFNB 1.21 1.00 1.05 OAS1-V 1.43 1.00 0.76 NT5C3-3 0.76 0.22 0.99 0.97 RGS20-V 0.31 0.10 0.99 0.93 4X GAS 1.30 0.23 0.98 1.27 MATR3-1 1.19 0.28 0.97 1.34 C13ORF18- 0.70 0.15 0.93 1.22 V CASP7-3 0.67 0.13 0.92 0.42 IFIT2-V 9.93 0.91 1.35 IFIT2-V L 1.07 0.91 1.35 GPB3-BV 2.02 0.90 0.88 IRF-9-74 1.13 0.88 1.15 IFNA4 1.79 0.29 0.87 1.36 C10O 8.32 0.87 0.94 ORF18 IFNA-17 1.45 0.37 0.86 1.40 NFKBI 1.53 0.85 1.02 USB18-V 1.22 0.82 1.09 DZIP1 0.79 0.05 0.80 0.70 PKR-1 0.84 0.25 0.74 0.88 3X GAS 1.60 0.26 0.73 1.34 VRE CON 1.40 0.09 0.60 1.71 SELPLG-M 1.89 0.81 0.56 1.32 ISG15 2.63 0.21 0.42 0.63 IFI44-2 1.30 0.23 0.40 0.59 CI3ORF18 0.81 0.37 0.81 CI3ORF18 0.88 0.40 0.37 0.81

(40) Several sequences caused the EGFP reporter to respond strongly to NDV when compared to IFN including the natural GBP1-V (SEQ ID NO:13) and IFIT3-1 sequence (SEQ ID NO:12), and the synthetic VRE-Con (SEQ ID NO:14) and AB-VRE sequences (SEQ ID NO:58) (FIG. 8 and Table 1). The strongest effect of reporter induction by NDV (15-20 fold) was observed in case of sequences derived from OAS3 promoter (SEQ ID NO:15, SEQ ID NO:16), but they were not selective as they are also induced by IFN. These responses are most likely due to NDV-induced endogenous IFN production that subsequently activates the IFN responsive promoters.

(41) There are also differential responses among different VRE/ISRE towards IFN during both early (4-8 hr) and late response (16-20 hr) as shown in FIGS. 8 and 9. The early response ranges from no IFN-induced fluorescence to strong response such as in the case of ISG15V and MX1-2 elements, respectively. Most of the virus-induced response appears as a later response; for example, responses to IFIT3-2 and MX1-2 elements-fused reporter were seen at a later time (16 hr) and was absent at the early time (6 hr; FIG. 9). Using these same sequence elements, there was strong early response to IFN-, but in comparison, late and weak response to IFN-y (FIG. 9).

Example 5

(42) Using QPCR, reporter mRNA levels were evaluated after transfection and expression of selected constructs (FIG. 10) AB-VRE, VRE-Con, GBP1-V, IFIT3-1, ISG15M, VREL1, GIP3-6-1, OAS3V2, IFIT-3-2, DDX58, PSMP9-V, CASP7-1. Those sequences that were selective for NDV at the protein fluorescence levels, were also the case at the mRNA levels (FIG. 10). The other sequences that were selective by IFN induction at the protein levels were not so at the mRNA levels. This may be due to the different mRNA and protein kinetics and involvement of coupled transcriptional/posttranscriptional effects due to specific IRF and sequence elements interactions. However, the endpoint assay of this approach is at fluorescence levels which is the most differential and simpler approach when compared to mRNA levels.

Example 6

(43) Based on the live cell fluorescence Pattern in IFN and NDV response, a subarray consisting of two to 13 constructs representing those differential virus response Patterns (FIG. 6) from a list that contains the following: AB VRE, AB-VRE-M2, B VRE 3X, GIP36-16, GPB1-V, IFIT3-1, IFIT3-2, IFNA-V, ISRE-74, MX-1, OAS3V, OAS3V2, PARP10S, SYN-ISRE-1, SYNVRE-1, SYNVRE-2, VRE Con, VRE-G1, VREL-1, VREL-2, VRE-G2, IFIT3-2S, SYN-ISRE-2R, ISGF15-M was utilized, for use with other types of viruses including both DNA and RNA viruses (FIG. 11). The GPB1-V sequence is largely of virus response with selective strong effect seen with respiratory syncytial virus (RSV; FIG. 11). On the other hand, NDV but not other viruses were able to induce reporter fluorescence due to sequence elements derived from PARP10 gene promoter. Other viruses did not induce any reporter fluorescence but several viruses were able to induce moderate levels of reporter fluorescence (FIG. 11). Thus, the cell-based multiple IFN/Virus response GFP reporter array offers research tool that is versatile and flexible to monitor and study the various anti-viral proteins such IFNs and different viruses. The data shows that heterogeneity and context sequence of the ISRE and VRE sequences influences both the strength and selectivity of responses. The use of GFP reporter allows further flexibility by monitoring at different time points, i.e., without experimental termination or cell lysis. This is also advantages in dissecting early and late responses which can used to distinguish between IFN and virus responses. Among the multiple IFN/Virus response reporters described here or from other promoter using the described approach, one can choose one or selected set for a specific IFN trigger or virus.

REFERENCES

(44) al-Haj, L., Al-Ahmadi, W., Al-Saif, M., Demirkaya, 0. & Khabar, K. S. Cloningfree regulated monitoring of reporter and gene expression. BMC Mol Biol 10, 20 (2009). Borden, E. C. et al. Interferons at age 50: past, current and future impact on biomedicine. Nut Rev Drug Discov 6, 975-990 (2007). Fray M D, Mann G E, Charleston B. 2001 Validation of an Mx/CAT reporter gene assay for the quantification of bovine type-I interferon. J Immunol Methods. 249(1-2):235-44. Halees, A. S., Leyfer, D. & Weiig, Z. PromoSer: a large-scale mammalian promoter and transcription start site identification sewice. Nucleic Acids Res 31, 3554-3559 (2003). Hitti, E. et al. A versatile ribosomal protein promoter-based reporter system for selective assessment of RNA stability and post-transcriptional control. RNA 16, 1245-1255 (2010). Khabar, K. S. et al. Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon. J Mol Biol 342, 833-846 (2004). Li, X. et al. Generation of destabilized green fluorescent protein as a transcription reporter. J Biol Chem 273, 34970-34975 (1998). Lleonart, R., Naf, D., Browning, H., and Weissmann, C. (1990). A novel, quantitative bioassay for type I interferon using a recombinant indicator cell line. Biotechnology (N Y) 8(12), 1263-7. Paun, A. & Pitha, P. M. The IRF family, revisited. Biochimie 89, 744-753 (2007). Pierre, G, Alexandra, V. & Ahmet, C. The role of differential expression of human interferonA genes in antiviral immunity. Cytokine & growth factor reviews 20, 283-295 (2009). Sato, M., Taniguchi, T. & Tanaka, N. The interferon system arid interferon regulatory factor transcription factorsstudies from gene knockout mice. Cytokine Growth Factor Rev 12, 133-142 (2001). Savitsky, D., Tamura, T., Yanai, H. & Taniguchi, T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunology, Immunotherapy 59, 489-510 (2010).